AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by AngioDynamics, Inc. on February 7, 2020, reporting events occurring on February 5, 2020. The filing focuses on executive leadership changes and associated compensatory arrangements rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and personnel, not a financial statement.
Material Changes
The primary material change reported is the appointment of Stephen A. Trowbridge as Executive Vice President and Chief Financial Officer, effective February 5, 2020. Mr. Trowbridge previously served as interim CFO since October 22, 2019, and Senior Vice President and General Counsel since August 2013.
Compensatory Arrangements and Outlook
In connection with the appointment, the Compensation Committee approved the following changes to Mr. Trowbridge's compensation:
- Base Salary: Increased to $400,000 annually.
- Annual Bonus: Target level of 60% of base salary.
- Equity Grant Target: Annual target level of 150% of base salary.
- Specific Grants (Effective Feb 3, 2020):
- Options to purchase 18,204 shares of common stock (vesting in four equal installments over four years; expiring Feb 3, 2030).
- 5,376 restricted stock units (vesting in four equal installments over four years).
Mr. Trowbridge will retain his role as General Counsel until a replacement is named. The filing does not contain specific guidance, risk factors, or management commentary regarding future financial performance.
Key Facts for Investor Verification
- Confirmation of Stephen A. Trowbridge's permanent appointment as CFO and EVP.
- Details of the equity grant exercise price (closing price on Feb 3, 2020) and vesting schedule.
- Timeline for the search and appointment of a new General Counsel.
- Impact of the interim CFO period on prior financial reporting periods (if any).